150 related articles for article (PubMed ID: 27349611)
1. Platelets surrounding primary tumor cells are related to chemoresistance.
Ishikawa S; Miyashita T; Inokuchi M; Hayashi H; Oyama K; Tajima H; Takamura H; Ninomiya I; Ahmed AK; Harman JW; Fushida S; Ohta T
Oncol Rep; 2016 Aug; 36(2):787-94. PubMed ID: 27349611
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
6. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.
Azrif M; Ibrahim J; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2011; 12(1):157-62. PubMed ID: 21517250
[TBL] [Abstract][Full Text] [Related]
9. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
12. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Denkert C; von Minckwitz G; Brase JC; Sinn BV; Gade S; Kronenwett R; Pfitzner BM; Salat C; Loi S; Schmitt WD; Schem C; Fisch K; Darb-Esfahani S; Mehta K; Sotiriou C; Wienert S; Klare P; André F; Klauschen F; Blohmer JU; Krappmann K; Schmidt M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Untch M; Loibl S
J Clin Oncol; 2015 Mar; 33(9):983-91. PubMed ID: 25534375
[TBL] [Abstract][Full Text] [Related]
14. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
15. The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.
Aloia A; Petrova E; Tomiuk S; Bissels U; Déas O; Saini M; Zickgraf FM; Wagner S; Spaich S; Sütterlin M; Schneeweiss A; Reitberger M; Rüberg S; Gerstmayer B; Agorku D; Knöbel S; Terranegra A; Falleni M; Soldati L; Sprick MR; Trumpp A; Judde JG; Bosio A; Cairo S; Hardt O
Breast Cancer Res; 2015 Nov; 17(1):146. PubMed ID: 26607327
[TBL] [Abstract][Full Text] [Related]
16. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
17. Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases.
Novell A; Morales S; Valls J; Panadés MJ; Salud A; Iglesias E; Vilardell F; Matias-Guiu X; Llombart-Cussac A
Histol Histopathol; 2017 Sep; 32(9):909-915. PubMed ID: 27905097
[TBL] [Abstract][Full Text] [Related]
18. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
[TBL] [Abstract][Full Text] [Related]
19. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
Horimoto Y; Arakawa A; Harada-Shoji N; Sonoue H; Yoshida Y; Himuro T; Igari F; Tokuda E; Mamat O; Tanabe M; Hino O; Saito M
Br J Cancer; 2015 Jan; 112(2):345-51. PubMed ID: 25422910
[TBL] [Abstract][Full Text] [Related]
20. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
